Tema Cardiovascular and Metabolics ETF Rating $30.72 -0.02 (-0.07%) As of 02/21/2025 03:34 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestTrends Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.79Holdings in HRTS have an aggregate rating of Moderate Buy based on 630 analyst ratings issued in the past year covering 37 companies (83.0% of the portfolio).HRTS Aggregate Price Target$30.72High Prediction$30.72Average Prediction$30.72Low Prediction$30.72Holdings in HRTS have an aggregate price target of $30.72 and a range of $30.72 to $30.72 covering 37 companies (83.0% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy8 Buy rating(s)Moderate Buy24 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 37 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings10.12%LLYEli Lilly and Company$874.12+0.1%4.8538 of 5 stars2.85$1,007.94 15.3%20Positive News6.00%UNHUnitedHealth Group$465.58-7.3%4.9912 of 5 stars3.05$629.32 35.2%22News CoverageGap DownHigh Trading Volume3.91%BBIOBridgeBio Pharma$36.85+0.1%4.8297 of 5 stars2.92$51.67 40.2%13Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap Up3.75%RHHBYRoche$41.42+0.7%N/A2.4373.72%ABTAbbott Laboratories$135.04+1.4%4.9028 of 5 stars2.83$133.06 -1.5%18Dividend AnnouncementPositive News3.56%VRTXVertex Pharmaceuticals$484.24+0.8%4.1184 of 5 stars2.65$505.61 4.4%26Analyst DowngradeInsider TradeAnalyst RevisionPositive News3.15%MRKMerck & Co., Inc.$89.40+2.0%5 of 5 stars2.58$116.39 30.2%24Analyst DowngradeOptions Volume3.12%BSXBoston Scientific$104.44-0.9%4.5031 of 5 stars3.00$107.39 2.8%23Analyst DowngradeInsider TradePositive News2.88%TMOThermo Fisher Scientific$532.55-1.0%4.7373 of 5 stars2.82$658.00 23.6%22Dividend IncreaseAnalyst RevisionPositive News2.72%MDTMedtronic$89.95+2.3%4.2706 of 5 stars2.38$95.00 5.6%16Earnings ReportAnalyst ForecastAnalyst Revision2.65%AMGNAmgen$303.01+1.7%4.4751 of 5 stars2.46$314.09 3.7%24Insider TradePositive News2.61%GILDGilead Sciences$109.95-0.1%4.7947 of 5 stars2.72$102.08 -7.2%29Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive News2.41%ABBVAbbVie$202.03+0.6%4.6572 of 5 stars2.88$208.35 3.1%24Dividend AnnouncementAnalyst RevisionPositive News2.07%CRNXCrinetics Pharmaceuticals$37.48+1.7%3.9214 of 5 stars2.92$72.64 93.8%132.03%EWEdwards Lifesciences$73.25-2.0%4.4403 of 5 stars2.42$79.95 9.1%261.96%DHRDanaher$209.86+0.9%4.992 of 5 stars2.71$278.00 32.5%21Dividend IncreaseAnalyst RevisionPositive News1.94%MASIMasimo$169.96-4.1%3.606 of 5 stars2.83$191.40 12.6%6Analyst RevisionNews Coverage1.93%PODDInsulet$282.80-1.9%4.3559 of 5 stars2.81$289.06 2.2%16Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading Volume1.92%ALNYAlnylam Pharmaceuticals$250.59-0.2%4.4628 of 5 stars2.72$299.48 19.5%25Analyst ForecastInsider Trade1.86%BMYBristol-Myers Squibb$55.85+0.1%4.5959 of 5 stars2.30$57.86 3.6%20Analyst RevisionPositive News1.84%REGNRegeneron Pharmaceuticals$700.33+0.6%4.6674 of 5 stars2.76$973.13 39.0%25Dividend Announcement1.71%CYTKCytokinetics$50.26-1.7%4.1939 of 5 stars2.94$82.00 63.2%18News Coverage1.52%MCKMcKesson$597.68-1.0%4.7147 of 5 stars2.94$645.79 8.0%16Insider TradePositive News1.47%DXCMDexCom$88.78-0.6%4.7551 of 5 stars2.94$99.06 11.6%18Positive News1.40%ASNDAscendis Pharma A/S$152.43-1.4%3.1733 of 5 stars2.93$197.36 29.5%14Analyst Forecast1.29%MDGLMadrigal Pharmaceuticals$336.23-4.2%3.2942 of 5 stars2.69$351.67 4.6%131.19%MREOMereo BioPharma Group$2.86-0.5%3.0514 of 5 stars3.43$7.83 174.4%7News Coverage0.96%RCKTRocket Pharmaceuticals$10.47-3.7%4.5267 of 5 stars2.92$47.27 351.5%120.94%MIRMMirum Pharmaceuticals$52.50-1.2%2.6731 of 5 stars3.09$57.10 8.8%11News Coverage0.94%AKROAkero Therapeutics$51.84+2.5%4.4064 of 5 stars3.00$75.86 46.3%9Insider Trade0.92%ARWRArrowhead Pharmaceuticals$19.90-5.1%4.1037 of 5 stars2.60$41.44 108.3%100.91%INSMInsmed$81.06-3.0%4.0523 of 5 stars3.00$91.00 12.3%15Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews Coverage0.89%GPCRStructure Therapeutics$23.70+1.3%2.4974 of 5 stars3.00$81.29 243.1%80.82%IONSIonis Pharmaceuticals$32.33-1.1%4.4271 of 5 stars2.70$60.00 85.6%20Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.73%WSTWest Pharmaceutical Services$210.72+3.5%4.9605 of 5 stars2.83$344.00 63.2%6Dividend AnnouncementAnalyst Downgrade0.65%VKTXViking Therapeutics$34.07+7.7%4.3911 of 5 stars3.00$97.29 185.5%15High Trading Volume0.49%NTLAIntellia Therapeutics$12.17-0.7%4.3943 of 5 stars2.72$48.71 300.2%18News CoverageGap Up This page (NASDAQ:HRTS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
